San Francisco, CA, United States of America

Philip A Leighton

This inventor holds 17 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Transgenic Antibody Production. Top assignees: Crystal Bioscience Inc., University of California. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip A Leighton. Retrieved from https://idiyas.com/inventor/philip-a-leighton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

16 out of 30

Crystal Bioscience Inc.

patents

1 out of 16,048

University of California

patents

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Transgenic Animals

Antibody Diversification

Gene Conversion

Immunoglobulin Genes

Heavy Chain Variable Domain

Light Chain Stabilization

Camelization

CDR Stabilization

Gene Trap Vectors

Transgenic Chickens

Antibody Production

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12588664 - Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion (2026-03-31),

2. 12568940 - TRANSGENIC CHICKEN HAVING AN ENDOGENOUS IMMUNOGLOBULIN HEAVY CHAIN GENE IN WHICH THE IGY CH1 CODING SEQUENCE IS FUNCTIONALLY DELETED (2026-03-10),

3. 12543710 - TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN II (2026-02-10),

4. 12428471 - Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion (2025-09-30),

5. 12408640 - Transgenic animal for producing diversified antibodies that have the same light chain I (2025-09-09),

6. 12102070 - Camelization of a human variable domain by gene conversion (2024-10-01),

7. 11542319 - Transgenic chicken comprising an inactivated immunoglobulin gene (2023-01-03),

8. 11337409 - Transgenic animal for producing diversified antibodies that have the same light chain I (2022-05-24),

9. 11033009 - Transgenic chicken for production of antibodies having a common light chain (2021-06-15),

10. 10689433 - Transgenic chicken comprising an inactivated immunoglobulin gene (2020-06-23),

11. 10687519 - Transgenic animal for production of antibodies having minimal CDRs (2020-06-23),

12. 10362770 - Transgenic animal for production of antibodies having minimal CDRs (2019-07-30),

13. 10172334 - Transgenic animal for production of antibodies having minimal CDRS (2019-01-08),

14. 10010058 - Transgenic animal for production of antibodies having minimal CDRS (2018-07-03),

15. 9809642 - Transgenic chicken comprising an inactivated immunoglobulin gene (2017-11-07),

Title: Innovations of Philip A. Leighton: A Pioneer in Transgenic Research

Introduction

Philip A. Leighton, located in San Francisco, CA, is an accomplished inventor with a notable portfolio of 12 patents. His innovative contributions to the field of transgenic animals and antibody diversification have paved the way for advancements in biotechnology and medical research.

Latest Patents

Among his latest patents is the groundbreaking invention related to the camelization of a human variable domain by gene conversion. This patent discloses a transgenic animal that utilizes gene conversion for antibody diversification. It involves B cells in which the endogenous immunoglobulin heavy chain locus comprises a functional immunoglobulin heavy chain gene encoding a human heavy chain variable domain, alongside a range of pseudogenes that facilitate nucleotide sequence donation through gene conversion. The invention enhances the potential for producing antibodies with camelizing amino acid substitutions.

Another significant patent is for a transgenic chicken featuring an inactivated immunoglobulin gene. This invention not only provides the basis for creating transgenic chickens with designed immunoglobulin genes but also includes cells and targeting vectors necessary for the development of such transgenic organisms.

Career Highlights

Philip has made substantial strides in his career through his roles in prominent organizations like Crystal Bioscience Inc. and the University of California. His work in these entities showcases his dedication to advancing scientific understanding in genetic engineering and transgenic applications.

Collaborations

Collaboration has been a key aspect of Philip A. Leighton's career. He has worked alongside notable colleagues such as William Don Harriman and Robert Etches, forming partnerships that have fostered innovative ideas and facilitated substantial advances in their respective fields.

Conclusion

Philip A. Leighton stands as a distinguished inventor whose groundbreaking patents and collaborations significantly contribute to the realm of biotechnology. His innovative spirit and commitment to research continue to inspire future developments in transgenic science and antibody diversification.

Profile summary based on public USPTO records.